{"id":"atra-ida","safety":{"commonSideEffects":[{"rate":null,"effect":"Differentiation syndrome (retinoic acid syndrome)"},{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Cardiotoxicity"},{"rate":null,"effect":"Mucositis"}]},"_chembl":{"chemblId":"CHEMBL461164","moleculeType":"Small molecule","molecularWeight":"133.10"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ATRA binds to retinoic acid receptors and promotes differentiation of APL blasts into mature granulocytes, while idarubicin is a topoisomerase II inhibitor that intercalates DNA and triggers apoptosis. The combination leverages differentiation therapy with chemotherapy to achieve high remission rates in acute promyelocytic leukemia, particularly in pediatric populations.","oneSentence":"ATRA (all-trans retinoic acid) differentiates acute promyelocytic leukemia cells while IDA (idarubicin) induces DNA damage and apoptosis in leukemic blasts.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:02:52.842Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute promyelocytic leukemia (APL) in pediatric patients"}]},"trialDetails":[{"nctId":"NCT02339740","phase":"PHASE3","title":"Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2015-07-21","conditions":"Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA","enrollment":158},{"nctId":"NCT04687176","phase":"PHASE2","title":"Frontline Oral Arsenic Trioxide for APL","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2021-01-01","conditions":"Acute Promyelocytic Leukemia","enrollment":100},{"nctId":"NCT02688140","phase":"PHASE3","title":"Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia","status":"COMPLETED","sponsor":"Technische Universität Dresden","startDate":"2016-06","conditions":"Acute Promyelocytic Leukemia","enrollment":135},{"nctId":"NCT04897490","phase":"","title":"RWE of 1st Line Treatment With ATO/ATRA for Adult APL","status":"RECRUITING","sponsor":"Grupo Argentino de Tratamiento de la Leucemia Aguda","startDate":"2021-03-01","conditions":"Promyelocytic Leukemia, Adult Acute","enrollment":50},{"nctId":"NCT00893399","phase":"PHASE3","title":"Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation","status":"COMPLETED","sponsor":"University of Ulm","startDate":"2010-05-12","conditions":"Acute Myeloid Leukemia","enrollment":600},{"nctId":"NCT00866918","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2009-03-09","conditions":"Childhood Acute Promyelocytic Leukemia With PML-RARA, Myeloid Neoplasm","enrollment":106},{"nctId":"NCT00482833","phase":"PHASE3","title":"Phase III Trial in Acute Promyelocytic Leukemia Patients","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2007-08","conditions":"Leukemia","enrollment":276},{"nctId":"NCT00003405","phase":"PHASE2","title":"Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"1998-04","conditions":"Leukemia","enrollment":""},{"nctId":"NCT02020161","phase":"PHASE4","title":"Clinical Guidelines for APL Treatment","status":"UNKNOWN","sponsor":"PETHEMA Foundation","startDate":"2012-06","conditions":"APL","enrollment":200},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT01064557","phase":"NA","title":"\"AIDA\" Protocol (LAP 0493)","status":"UNKNOWN","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"1993-10","conditions":"Leukemia","enrollment":1068},{"nctId":"NCT01987297","phase":"PHASE4","title":"Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2012-06","conditions":"Acute Promyelocytic Leukemia","enrollment":738},{"nctId":"NCT00413166","phase":"PHASE2","title":"All-trans Retinoic Acid, and Arsenic +/- Idarubicin","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-12","conditions":"Acute Promyelocytic Leukemia","enrollment":78},{"nctId":"NCT00151242","phase":"PHASE2, PHASE3","title":"Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of Ulm","startDate":"2004-07","conditions":"Acute Myeloid Leukemia","enrollment":920},{"nctId":"NCT00151255","phase":"PHASE3","title":"All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of Ulm","startDate":"2004-06","conditions":"Acute Myeloid Leukemia","enrollment":500},{"nctId":"NCT01226303","phase":"PHASE3","title":"Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia","status":"UNKNOWN","sponsor":"Associazione Italiana Ematologia Oncologia Pediatrica","startDate":"2009-01","conditions":"Acute Promyelocytic Leukemia","enrollment":300},{"nctId":"NCT00528450","phase":"PHASE2","title":"Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia","status":"TERMINATED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-09","conditions":"Leukemia","enrollment":1},{"nctId":"NCT01067274","phase":"PHASE3","title":"ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML)","status":"WITHDRAWN","sponsor":"Acute Leukemia French Association","startDate":"2010-04","conditions":"Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT00408278","phase":"PHASE4","title":"Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2005-07","conditions":"Acute Promyelocytic Leukemia","enrollment":300},{"nctId":"NCT00378365","phase":"PHASE3","title":"Acute Promyelocytic Leukemia 2006 (APL)","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2006-10","conditions":"Leukemia, Promyelocytic, Acute","enrollment":800},{"nctId":"NCT00002658","phase":"PHASE3","title":"Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Medical Research Council","startDate":"1994-01","conditions":"Leukemia, Neutropenia","enrollment":2000},{"nctId":"NCT00005823","phase":"PHASE3","title":"Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Leukemia Research Fund","startDate":"1998-12","conditions":"Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms","enrollment":2000},{"nctId":"NCT00002701","phase":"PHASE3","title":"Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia","status":"UNKNOWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1995-10","conditions":"Leukemia","enrollment":750},{"nctId":"NCT00016159","phase":"PHASE2","title":"Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2000-11","conditions":"Leukemia","enrollment":35},{"nctId":"NCT00465933","phase":"PHASE4","title":"Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA)","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"1999-03","conditions":"Acute Promyelocytic Leukemia","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ATRA + IDA","genericName":"ATRA + IDA","companyName":"Associazione Italiana Ematologia Oncologia Pediatrica","companyId":"associazione-italiana-ematologia-oncologia-pediatrica","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ATRA (all-trans retinoic acid) differentiates acute promyelocytic leukemia cells while IDA (idarubicin) induces DNA damage and apoptosis in leukemic blasts. Used for Acute promyelocytic leukemia (APL) in pediatric patients.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}